Why the study?
Diabetes mellitus promotes cardiac arrhythmias while melatonin has antiarrhythmic effects, and their overlapping cellular targets warranted testing melatonin as an antiarrhythmic agent in DM.
Does melatonin prevent arrhythmias and electrophysiological changes in an experimental diabetic cardiomyopathy rat model?
Population
41 control and 71 diabetic rats
Comparison
Oral melatonin (10 mg/kg daily) vs placebo
Design
Animal experimental study
Follow-up
1 month
Key result
Melatonin treatment in diabetic rats mitigated myocardial fibrosis and prevented diabetes-related electrophysiological changes and reperfusion ventricular tachycardia/fibrillation.
Authors
Loading...
May support melatonin for arrhythmia prevention in diabetic cardiomyopathy models; leaves open human translation.
Does melatonin prevent arrhythmias and electrophysiological changes in an experimental diabetic cardiomyopathy rat model?
Melatonin confers antiarrhythmic effects and mitigates electrophysiological changes and myocardial fibrosis in a rat model of diabetic cardiomyopathy.
Ovechkin et al. (2026) studied Experimental diabetic cardiomyopathy (n=112). Melatonin vs. Placebo was evaluated on Electrophysiological and antiarrhythmic properties (including conduction velocity, repolarization, and reperfusion ventricular tachycardia/fibrillation). Melatonin treatment in diabetic rats mitigated myocardial fibrosis and prevented diabetes-related electrophysiological changes and reperfusion ventricular tachycardia/fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: